AG˹ٷ

STOCK TITAN

Integer Appoints Michael Coyle to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Integer Holdings (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), has appointed Michael Coyle to its Board of Directors. Coyle, who brings over 40 years of medical device industry experience, will serve on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.

Coyle's extensive background includes serving as president and CEO of iRhythm Technologies, executive vice president at Medtronic's cardio and vascular group, and leadership roles at St. Jude Medical and Eli Lilly. He currently serves on the boards of Haemonetics Corporation and BaroPace, and holds six U.S. patents in cardiovascular medical device technologies.

Integer Holdings (NYSE:ITGR), un'importante organizzazione di sviluppo e produzione su contratto di dispositivi medici (CDMO), ha nominato Michael Coyle nel suo Consiglio di Amministrazione. Coyle, con oltre 40 anni di esperienza nel settore dei dispositivi medici, farà parte del Comitato di Revisione, del Comitato per la Retribuzione e l'Organizzazione e del Comitato per la Strategia Tecnologica.

Il vasto percorso professionale di Coyle include la carica di presidente e CEO di iRhythm Technologies, vicepresidente esecutivo del gruppo cardio e vascolare di Medtronic, oltre a ruoli di leadership presso St. Jude Medical ed Eli Lilly. Attualmente è membro dei consigli di amministrazione di Haemonetics Corporation e BaroPace, e detiene sei brevetti statunitensi nelle tecnologie dei dispositivi medici cardiovascolari.

Integer Holdings (NYSE:ITGR), una destacada organización de desarrollo y fabricación por contrato de dispositivos médicos (CDMO), ha nombrado a Michael Coyle en su Junta Directiva. Coyle, con más de 40 años de experiencia en la industria de dispositivos médicos, formará parte del Comité de Auditoría, del Comité de Compensación y Organización, y del Comité de Estrategia Tecnológica.

La amplia trayectoria de Coyle incluye haber sido presidente y CEO de iRhythm Technologies, vicepresidente ejecutivo del grupo cardiovascular de Medtronic, y cargos de liderazgo en St. Jude Medical y Eli Lilly. Actualmente, forma parte de los consejos de administración de Haemonetics Corporation y BaroPace, y posee seis patentes estadounidenses en tecnologías de dispositivos médicos cardiovasculares.

Integer Holdings (NYSE:ITGR)� 선도적인 의료기기 계약 개발 � 제조 조직(CDMO)으로� Michael Coyle� 이사회에 임명했습니다. Coyle은 40� 이상� 의료기기 산업 경력� 보유하고 있으�, 감사위원�, 보상 � 조직위원�, 기술 전략위원회에� 활동� 예정입니�.

Coyle� 폭넓은 경력에는 iRhythm Technologies� 사장 � CEO, Medtronic 심혈관 그룹� 부사장, St. Jude Medical � Eli Lilly에서� 리더� 역할� 포함됩니�. 현재 Haemonetics Corporation� BaroPace 이사회에� 활동 중이�, 심혈관 의료기기 기술 분야에서 6건의 미국 특허� 보유하고 있습니다.

Integer Holdings (NYSE:ITGR), une organisation leader dans le développement et la fabrication sous contrat de dispositifs médicaux (CDMO), a nommé Michael Coyle à son conseil d'administration. Coyle, qui possède plus de 40 ans d'expérience dans l'industrie des dispositifs médicaux, siégera au comité d'audit, au comité de rémunération et d'organisation, ainsi qu'au comité de stratégie technologique.

Le parcours étendu de Coyle inclut des postes de président et CEO chez iRhythm Technologies, de vice-président exécutif du groupe cardio-vasculaire chez Medtronic, ainsi que des rôles de direction chez St. Jude Medical et Eli Lilly. Il siège actuellement aux conseils d'administration de Haemonetics Corporation et BaroPace, et détient six brevets américains dans les technologies des dispositifs médicaux cardiovasculaires.

Integer Holdings (NYSE:ITGR), ein führendes Unternehmen im Bereich der Vertragsentwicklung und -fertigung von Medizinprodukten (CDMO), hat Michael Coyle in seinen Vorstand berufen. Coyle bringt über 40 Jahre Erfahrung in der Medizinproduktebranche mit und wird im Prüfungsausschuss, im Vergütungs- und Organisationsausschuss sowie im Ausschuss für Technologiestrategie tätig sein.

Coyles umfangreicher Hintergrund umfasst die Positionen als Präsident und CEO von iRhythm Technologies, Executive Vice President der kardiovaskulären Gruppe bei Medtronic sowie Führungsrollen bei St. Jude Medical und Eli Lilly. Derzeit sitzt er im Vorstand von Haemonetics Corporation und BaroPace und hält sechs US-Patente im Bereich kardiovaskulärer Medizintechnologien.

Positive
  • Appointment of highly experienced medical device industry veteran with 40+ years of leadership
  • New director brings valuable expertise in cardiovascular technologies with 6 U.S. patents
  • Strategic addition to strengthen board oversight in technology and medical device manufacturing
Negative
  • None.

~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~

PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors.

Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.

He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Before that, he was executive vice president and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career.

Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies, Inc. and Volcano Corporation.

He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies.

“Integer’s Board regularly evaluates its composition to ensure it encompasses the appropriate skills, background and perspectives necessary to drive growth for Integer’s shareholders,� said Pamela Bailey, Integer Board Chair. “We are pleased to welcome Michael Coyle, whose extensive medical device industry experience and proven leadership in global business and technology will contribute significantly to our strategic initiatives and culture.�

“The executive leadership team and I look forward to working with Michael as we execute our strategy to deliver sustained outperformance,� said Joseph Dziedzic, Integer president and CEO. “We are confident Michael's expertise will contribute to Integer’s contract development and manufacturing outsourcing strategy, furthering our position as our customers� partner of choice for innovative medical technologies and services as we realize our vision to enhance the lives of patients worldwide.�

About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at .

Investor Relations:Media Relations:
Kristen StewartKelly Butler
[email protected][email protected]
551.337.3973469.731.6617

FAQ

Who is Michael Coyle, the new board member of Integer Holdings (NYSE:ITGR)?

Michael Coyle is a medical device industry veteran with over 40 years of experience, former CEO of iRhythm Technologies and executive VP at Medtronic's cardio and vascular group. He holds 6 U.S. patents in cardiovascular medical devices.

What committees will Michael Coyle serve on Integer's Board?

Michael Coyle will serve on three committees: the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.

What is Michael Coyle's educational background?

Michael Coyle holds an MBA from the Wharton School of Business at the University of Pennsylvania and a bachelor's degree from Case Western Reserve University.

What other board positions does Michael Coyle currently hold?

Michael Coyle currently serves as a director on the boards of Haemonetics Corporation and BaroPace.
Integer Hldgs Corp

NYSE:ITGR

ITGR Rankings

ITGR Latest News

ITGR Latest SEC Filings

ITGR Stock Data

4.23B
33.89M
1.85%
121.18%
6.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States
PLANO